Navigation Links
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
Date:10/27/2014

LONDON, October 27, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Friday, shares in Neurocrine Biosciences Inc. traded between $16.95 and $17.57 before ending the session 1.98% higher at $17.51. The stock reported a trading volume of 0.59 million shares, close to its three months average volume of 0.53 million shares. Neurocrine Biosciences Inc.'s shares have surged 7.03% in the last one month, 29.42% in the previous three months and 87.47% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $15.99 and $15.49, respectively. Moreover, shares of Neurocrine Biosciences Inc. have a Relative Strength Index (RSI) of 61.68. Sign up and read the free notes on NBIX at:

www.Investor-Edge.com/NBIX-27Oct2014

Insmed Inc.'s stock edged 0.42% lower, to close the day at $14.27. The stock recorded a trading volume of 0.47 million shares, below its three months average volume of 0.79 million shares. The stock oscillated between $13.92 and $14.52 during the session. Over the last three trading sessions and over the past one month, Insmed Inc.'s shares have gained 4.70% and 6.33%, respectively. However, the stock has lost 16.06% since the start of this year. The company's stock is trading above its 50-day moving average of $13.54, while the 50-day moving average is below Insmed Inc. stock's 200-day moving average of $15.97. Additionally, Insmed Inc.'s stock has an RSI of 59.28. The complimentary notes on INSM can be downloaded as in PDF format at:

www.Investor-Edge.com/INSM-27Oct2014

On Friday, shares in BioCryst Pharmaceuticals Inc. recorded a trading volume of 1.27 million shares, lower than its three months average volume of 1.42 million shares. The stock ended the day at an intra-day low of $11.83, which was 2.95% below its previous day's closing of $12.19. The stock fluctuated between $11.83 and $12.69 during the trading session. BioCryst Pharmaceuticals Inc.'s shares have advanced 4.05% in the previous three trading sessions, 11.60% in the last one month and 55.66% on YTD basis. The company's stock is trading above its 200-day moving average of $11.00. Furthermore, shares of BioCryst Pharmaceuticals Inc. have an RSI of 52.55. Register for free on Investor-Edge and access the latest research on BCRX at:

www.Investor-Edge.com/BCRX-27Oct2014

Dyax Corp.'s stock edged 0.65% higher, to close Friday's session at $10.81, after oscillating between $10.64 and $10.91. The stock recorded a trading volume of 1.12 million shares, above its three months average volume of 0.97 million shares. Dyax Corp.'s shares have advanced 6.08% in the previous three trading sessions and 21.05% in the last three months. Additionally, from the beginning of 2014, the stock has gained an upside of 43.46%. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $10.17 is above its 200-day moving average of $8.94. Further, Dyax Corp.'s stock has an RSI of 62.37. The complete research on DYAX is available for free at:

www.Investor-Edge.com/DYAX-27Oct2014

Oncothyreon Inc.'s stock finished Friday's session 2.17% lower at $1.80. A total of 0.47 million shares were traded, which was below its three months average volume of 0.69 million shares. The stock moved between $1.79 and $1.87 during the session. Over the last three trading sessions and the previous one month, Oncothyreon Inc.'s shares have declined 5.26% and 11.76%, respectively. However, the stock has gained 2.27% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $2.69 is greater than its 50-day moving average of $2.11. Oncothyreon Inc.'s stock has an RSI of 42.30. Free in depth research on ONTY is available at:

www.Investor-Edge.com/ONTY-27Oct2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



'/>"/>
SOURCE Investor-Edge
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
2. Portage announces conversion of its debt into equity
3. China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang
4. SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy
5. Metabolix, Inc. Enters into Private Placement Agreement with Investors to Raise $25 Million in Equity Financing
6. Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org
7. Genufood Energy Enzymes Corp. Announces $20 Million Equity Purchase Agreement
8. Ironridge Global Partners, LLC Successfully Concludes Equity Financings of ULURU Inc.
9. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
10. The EQUITY Series of Business/Medical Thrillers by Award-winning Author Rudy Mazzocchi, Continue to Climb the Charts
11. Manipulating the Brain to Eliminate Fear or Restore Memories – Rudy Mazzocchi Releases the 2nd Novel in The EQUITY Series entitled "EQUITY of FEAR"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2020)... SAN DIEGO (PRWEB) , ... July 06, 2020 , ... ... a new program featuring up to 200 million stem cells. Depending on the patient's ... of seniors in the US will die having some form of Alzheimers dementia, and ...
(Date:7/1/2020)... WESTMINSTER, Colo. (PRWEB) , ... ... ... providers of expert tissue data insights, today announced that the launch of ... PD-L1 results along with data about the tumor microenvironment (TME). , “Flagship’s ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
(Date:6/23/2020)... ... 2020 , ... Dracen Pharmaceuticals Inc., announced today that two ... the American Association for Cancer Research Virtual meeting. One poster describes the immuno-metabolism ... agent activity in KEAP1 mutant tumor models of NSCLC. , “As ...
Breaking Biology Technology:
(Date:6/5/2020)... ... , ... Greffex, a pioneering vaccine and gene therapy company based in Houston, ... need for a global perspective to make an impact in a post pandemic world,” ... as an independent, director of the company. , “The Greffex board is excited to ...
(Date:5/30/2020)... (PRWEB) , ... May 29, 2020 , ... ... of digital transformation for enterprises globally, has collaborated with EchoNous Inc. to develop ... It can measure systolic heart function, which has been clinically tested versus ...
(Date:5/28/2020)... ... 2020 , ... Today bioinformatics leader hc1® announced ... lab testing insights and hc1’s exclusive Local Risk Index in a unified CV19 ... employees returning to the workplace. , “Some of the best ways to keep ...
Breaking Biology News(10 mins):